NHS to Fast-Track Patients into mRNA Cancer Vaccine Trial
The investigational vaccine is designed to help the immune system recognise and destroy cancer cells containing human papillomavirus (HPV) proteins. NHS England said more than 100 patients will be matched to the trial over the next year at 15 NHS hospitals.
Third Trial via Cancer Vaccine Launch Pad
This is the third cancer vaccine study run through NHS England's Cancer Vaccine Launch Pad (CVLP), a national programme that matches eligible patients with nearby trials.
Other CVLP trials are investigating vaccines for patients with colorectal carcinoma and with melanoma. The initiative is coordinated by the University of Southampton's Clinical Trials Unit.
Difficult to Treat, High Recurrence
More than 11,000 new head and neck cancer cases are diagnosed each year in England. Despite improvements in care, the advanced form of the disease is difficult to treat and has high rates of recurrence, with 2-year survival rates below 50%.
The investigational vaccine, known as BNT113, encodes two oncoproteins commonly found in HPV16-positive head and neck squamous cell carcinoma – the most common type, accounting for 95% of these types of cancers.
The AHEAD-MERIT trial is an open-label phase II/III randomised study. It will assess BNT113 in combination with pembrolizumab, a PD-1 inhibitor, versus pembrolizumab alone as a first-line treatment for patients with unresectable, recurrent, or metastatic HPV16-positive head and neck cancers expressing PD-L1.
'Potentially Transformative' Approach
Professor Peter Johnson, NHS England's national clinical director for cancer, called the vaccine 'potentially transformative' and said it offered 'renewed hope of holding the disease at bay'.
Chris Curtis, who was diagnosed with HPV-related head and neck cancer in 2011 and founded the support charity The Swallows, said the vaccine could help people 'get on with their lives and move forward'.
Expanding Access to Personalised Treatment
The CVLP is part of a strategic partnership between NHS England, the government, and BioNTech. NHS England said it has accelerated cancer trial activity, with faster site activation and enrolment compared with standard processes.
The programme aims to match thousands more cancer patients to vaccine and immunotherapy trials in the future.
In April, NHS England announced that patients with advanced melanoma would be fast-tracked into the SCOPE study, a clinical trial for a new cancer vaccine.
Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the CVLP was 'an important route to fast-track promising mRNA vaccine technology into clinical trials.' He added, 'Research into personalised cancer treatments is vital.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Woman's snoring was symptom of rare form of cancer: 'Don't ignore it'
A mother in the U.K. who began snoring for the first time in her life was stunned to learn the unexpected symptom was a sign of a rare and potentially life-threatening cancer. "I started snoring, which I'd never done before," she recalled. "I was waking myself up, breathing through my mouth rather than my nose." Claire Barbery, 51, initially brushed off the blockage on one side of her nose, blaming it on the after-effects of Covid-19 or irritation from frequent testing while working at a care facility, as reported by SWNS. Doctors Reveal Key Signs Of Lyme Disease As Tick Season Intensifies Across Us It wasn't until the persistent congestion worsened and she started snoring in her sleep that she sought medical advice. "I very nearly canceled that appointment because I didn't want to be wasting NHS time," Barbery said, per SWNS. "There's nothing wrong, I thought. But looking back, that decision could have cost me my life." Read On The Fox News App Barbery tried using a steroid spray without success before being referred to an ear, nose, and throat (ENT) specialist in January 2023. After undergoing scans and a biopsy, she was diagnosed with olfactory neuroblastoma, a rare type of cancer that develops in the upper part of the nasal cavity. Doctors discovered a 5-centimeter tumor that had already begun eroding the bone at the base of Barbery's skull. Forget 10,000 Steps — Research Reveals The Real Number You Need For Better Health It was a dangerous and complex case requiring urgent intervention. The surgery was performed at Queen Elizabeth Hospital in Birmingham by consultant surgeon Shahz Ahmed, a skull base specialist, SWNS reported. The procedure, which was featured in the Channel 5 documentary "Surgeons: A Matter of Life or Death," involved removing the tumor along with Barbery's olfactory bulbs, leaving her with a permanent loss of smell. "Claire had a very rare form of cancer that needed to be removed," Ahmed said in the report. "Untreated, it could have metastasized and spread into the neck and the rest of the body." Because the tumor had already spread through the skull base into the bottom of the brain, the surgery posed serious risks due to the proximity to vital structures. "The key worries were operating between the left and the right eye," Ahmed said. "The main blood supply to the brain is in very close proximity, so the risk of seizures, stroke, injury to the brain and loss of life were all very real." The surgery was a success and there were no complications. Following the procedure, Barbery underwent six weeks of chemotherapy and radiotherapy. She is now under regular medical monitoring and continues to recover, gradually returning to work and enjoying time with her husband and daughters, SWNS reported. Now living in Newquay, Cornwall, Barbery is using her experience to advocate for awareness of head and neck cancers. Click Here To Sign Up For Our Health Newsletter She recently partnered with the Get A-Head Charitable Trust to raise awareness for World Head and Neck Cancer Day. "If you know your body, then you've got to push," she said. "If there's something wrong, don't ignore it." According to SWNS, Barbery's case is a reminder that even minor or unusual symptoms, like snoring, can sometimes be signs of something far more serious. For more Health articles, visit Looking back, Barbery said she's grateful she went to the appointment she almost canceled. "Even then, I didn't want to waste anyone's time," she admitted. "But that decision ended up saving my life."Original article source: Woman's snoring was symptom of rare form of cancer: 'Don't ignore it' Solve the daily Crossword
Medscape
2 hours ago
- Medscape
Coronary Sinus Reducer Shows Promise, With Caveats
The coronary sinus reducer, an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But a meta-analysis published today in JACC: Cardiovascular Interventions found the benefits of the intervention are likely smaller than those early studies predicted. 'There have been lots of unblinded single-arm studies [of the procedure] but only three randomized controlled trials, so we wanted to look at the different effect sizes to better understand the overall potential efficacy,' said Rasha Al-Lamee, MD, a cardiologist at the National Heart and Lung Institute, part of Imperial College London, London, England, who led the meta-analysis. Al-Lamee and her colleagues looked at data from a combined total of 180 patients in the three trials, as well as 13 single-arm studies with 668 total patients. They found the coronary sinus procedure to be safe, with a success rate of 98.3%. But while both the single-arm and the controlled trials demonstrated improvements in symptoms of angina, the effect size was much smaller in the controlled trials. In the more rigorous trials, 26% of patients experienced at least a one-class improvement and 17% had at least a two-class improvement on the Canadian Cardiovascular Society classification of angina. Those figures were about one third of the gains reported in the single-arm trials. What's more, the randomized controlled trials found no evidence of benefit based on continuous measurements such as the Seattle Angina Questionnaire. Nor did they find improvements in objective measures such as myocardial perfusion associated with the intervention. Deepak Bhatt, MD, a cardiologist at the Icahn School of Medicine at Mount Sinai in New York City, who co-wrote an editorial accompanying the journal article, said more treatment options are needed for patients with refractory angina, who have often exhausted all other medical therapies and surgical procedures. But while coronary sinus reduction shows promise, the meta-analysis demonstrates why more, and larger, trials will be needed before clinicians can use it more broadly. 'It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients,' he told Medscape Medical News . 'History is littered with examples of things we were convinced worked but really didn't.' Percutaneous laser therapy, for example, seemed to show benefits for refractory angina at first, but more rigorous randomized trials found no benefit from the procedure, he said. The coronary sinus reducer device is already approved in the UK and Europe and its use is on the rise there, said Al-Lamee, but it has not yet been approved in the US. The ongoing COSIRA-II trial, with an estimated enrollment of 380 patients, should be well-powered enough to provide definitive results and support US approval, she said. Should COSIRA-II show definite benefit, she added, the device may become more of a frontline treatment, used before riskier revascularization options. 'Why have a redo of coronary artery bypass surgery if you have a device that is safe and effective?' she said. Al-Lamee had received consulting and speaker fees from Shockwave Medical, which makes the CSR device. Bhatt reported no relevant financial conflicts.
Fox News
4 hours ago
- Fox News
Woman's snoring was symptom of rare form of cancer: 'Don't ignore it'
A mother in the U.K. who began snoring for the first time in her life was stunned to learn the unexpected symptom was a sign of a rare and potentially life-threatening cancer. "I started snoring, which I'd never done before," she recalled. "I was waking myself up, breathing through my mouth rather than my nose." Claire Barbery, 51, initially brushed off the blockage on one side of her nose, blaming it on the after-effects of COVID-19 or irritation from frequent testing while working at a care facility, as reported by SWNS. It wasn't until the persistent congestion worsened and she started snoring in her sleep that she sought medical advice. "I very nearly canceled that appointment because I didn't want to be wasting NHS time," Barbery said, per SWNS. "There's nothing wrong, I thought. But looking back, that decision could have cost me my life." Barbery tried using a steroid spray without success before being referred to an ear, nose, and throat (ENT) specialist in January 2023. After undergoing scans and a biopsy, she was diagnosed with olfactory neuroblastoma, a rare type of cancer that develops in the upper part of the nasal cavity. Doctors discovered a 5-centimeter tumor that had already begun eroding the bone at the base of Barbery's skull. It was a dangerous and complex case requiring urgent intervention. The surgery was performed at Queen Elizabeth Hospital in Birmingham by consultant surgeon Shahz Ahmed, a skull base specialist, SWNS reported. "If there's something wrong, don't ignore it." The procedure, which was featured in the Channel 5 documentary "Surgeons: A Matter of Life or Death," involved removing the tumor along with Barbery's olfactory bulbs, leaving her with a permanent loss of smell. "Claire had a very rare form of cancer that needed to be removed," Ahmed said in the report. "Untreated, it could have metastasized and spread into the neck and the rest of the body." Because the tumor had already spread through the skull base into the bottom of the brain, the surgery posed serious risks due to the proximity to vital structures. "The key worries were operating between the left and the right eye," Ahmed said. "The main blood supply to the brain is in very close proximity, so the risk of seizures, stroke, injury to the brain and loss of life were all very real." The surgery was a success and there were no complications. Following the procedure, Barbery underwent six weeks of chemotherapy and radiotherapy. She is now under regular medical monitoring and continues to recover, gradually returning to work and enjoying time with her husband and daughters, SWNS reported. Now living in Newquay, Cornwall, Barbery is using her experience to advocate for awareness of head and neck cancers. She recently partnered with the Get A-Head Charitable Trust to raise awareness for World Head and Neck Cancer Day. "If you know your body, then you've got to push," she said. "If there's something wrong, don't ignore it." According to SWNS, Barbery's case is a reminder that even minor or unusual symptoms, like snoring, can sometimes be signs of something far more serious. For more Health articles, visit Looking back, Barbery said she's grateful she went to the appointment she almost canceled. "Even then, I didn't want to waste anyone's time," she admitted. "But that decision ended up saving my life."
